NCT00382993 - A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) | Biotech Hunter

Enrollment

169

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Migraine Disorders

Interventions

DRUG

Placebo

Matching placebo tablet

DRUG

Combination Product (sumatriptan succinate/naproxen sodium)

Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in second layer.

Trial Locations (28)

14221

GSK Investigational Site, Williamsville

18103

GSK Investigational Site, Allentown

19107

GSK Investigational Site, Philadelphia

21208

GSK Investigational Site, Pikesville

29412

GSK Investigational Site, Charleston

30901

GSK Investigational Site, Augusta

31405

GSK Investigational Site, Savannah

33180

GSK Investigational Site, Aventura

35501

GSK Investigational Site, Jasper

37203

GSK Investigational Site, Nashville

38018

GSK Investigational Site, Memphis

43081

GSK Investigational Site, Westerville

48104

GSK Investigational Site, Ann Arbor

50314

GSK Investigational Site, Des Moines

60062

GSK Investigational Site, Northbrook

63141

GSK Investigational Site, St Louis

68114

GSK Investigational Site, Omaha

71103

GSK Investigational Site, Shreveport

75231

GSK Investigational Site, Dallas

78258

GSK Investigational Site, San Antonio

92056

GSK Investigational Site, Oceanside

94109

GSK Investigational Site, San Francisco

98104

GSK Investigational Site, Seattle

06106

GSK Investigational Site, Hartford

02215

GSK Investigational Site, Boston

01605

GSK Investigational Site, Worcester

08084

GSK Investigational Site, Stratford

43614-5809

GSK Investigational Site, Toledo